Local delivery systems that provide sustained, high concentrations of antitumor cytokines in the tumor microenvironment while minimizing systemic dissemination are needed to realize the potential of cytokine-based immunotherapies. Recently, co-formulations of cytokines with chitosan solutions have been shown to increase local cytokine retention and bioactivity. In particular, intratumoral (i.t.) injections of chitosan/IL-12 can eliminate established tumors and generate tumor-specific immune responses. In the present study, we explored the mechanisms by which chitosan potentiated IL-12's antitumor activity. The location of chitosan/IL-12 injection was found to be critical for optimal cytokine delivery. I.t. injections eliminated 9 of 10 MC38 adenocarcinomas while contralateral and peritumoral injections delayed tumor growth but could not eliminate tumors. Microdosing studies demonstrated that IL-12 depots, simulated through daily i.t. injections with IL-12 alone, were not as effective as weekly i.t. chitosan/IL-12. 50e75% of mice receiving daily IL-12 microdoses and 87.5% of mice receiving weekly chitosan/IL-12 were cured of MC38 tumors. Chitosan was found to increase IL-12-mediated leukocytic expansion in tumors and tumordraining lymph nodes (TDLNs) by 40 and 100%, respectively. Immunophenotyping studies demonstrated that chitosan co-formulation amplified IL-12-induced increases in important effector populations, such as CD8
Introduction
Since the discovery of 'endogenous pyrogen,' now known as IL-1, in 1953 [1] , the use of exogenous cytokines to treat malignant neoplasms has been well studied and heavily pursued. However, only 2 of 40þ identified cytokines, IFN-a and IL-2, are approved as single agent immunotherapies for a limited number of indications. IFN-a therapy yields an 80% overall response rate with 10% complete responses in hairy cell leukemia [2] , 40% objective response rate in AIDS-related Kaposi's sarcoma [3, 4] , and 10e20% complete response rate in chronic myelogenous leukemia [5, 6] . IL-2 therapy yields 10e20% overall response rates with about 5% complete responses in both metastatic renal cell carcinoma [7e9] and metastatic melanoma [8, 10, 11] .
Both IFN-a and IL-2 are administered as systemic injections and cause significant adverse events. In particular, systemic IL-2 often requires intensive care due to grade 3 and 4 adverse events including fever, transaminase elevation, hypotension and edema. Nearly all clinical trials, both past and present, evaluating cytokine monotherapies utilize systemic (i.v., s.c. or i.m.) injections. However, cytokines function primarily through paracrine and autocrine mechanisms and thus are rarely measurable in the circulation of healthy individuals.
We and others have noted that cytokine-based immunotherapies would be more effective and less toxic if delivered locally and maintained in a tissue of interest, i.e. the tumor. Furthermore, a growing mountain of evidence demonstrates that locally administered cytokines can generate adaptive immunological memory capable of controlling metastasis and preventing recurrence [12e14] . This "local-to-systemic" antitumor immunity encourages re-evaluation of systemic cytokine delivery and justifies the development of localized delivery strategies capable of maximizing cytokine delivery to the tumor microenvironment while minimizing toxicities associated with systemic dissemination of potent, pro-inflammatory cytokines.
Here, we continue our investigation of simple co-formulations of chitosan solution with recombinant cytokines for local administration. Chitosan is a nontoxic (LD50 > 16 g/kg) [15] , biodegradable, natural polysaccharide derived from the exoskeletons of crustaceans. Chitosan is a widely used biomaterial with an established safety profile in humans. It is used as a pharmaceutical excipient [16] , a weight-loss supplement, an experimental mucosal adjuvant [17] and in an FDA-approved hemostatic dressing [18] .
Our previous studies have demonstrated that simple, viscous chitosan solutions are able to maintain high concentrations of co-formulated recombinant cytokines and/or protein antigens following intratumoral (i.t.) or s.c. administration [19e22] . In particular, i.t. injections of co-formulated chitosan and recombinant IL-12 (chitosan/IL-12) were found to eliminate flank MC38 and Panc02 tumors [22] . The ability of chitosan to enhance the retention of IL-12 in the tumor microenvironment was thought to be primarily responsible for the increased antitumor activity. However, the importance of injecting the depot formulation directly into the tumor was not explored. It is possible that sustained systemic release of IL-12 from a distal site, similar to gene-based IL-12 delivery strategies [23e25], may have produced comparable results. In addition, although chitosan alone exhibited no antitumor activity [21, 22] , we did not explicitly rule out the possibility that chitosan modulates the immunologic potential of IL-12 through manipulation of local immune cell phenotypes.
The goal of the present study was to understand the mechanisms by which chitosan potentiates cytokine bioactivity. Does chitosan simply amplify cytokine bioactivity through enhanced retention or does chitosan induce an immune response capable of synergizing with cytokine function? To explore the effect of local vs. distal IL-12 depots, we characterized the antitumor activities of chitosan/IL-12 injected adjacent to the tumor, contralateral to the tumor or i.t. To isolate the effect of enhanced IL-12 retention in the tumor on antitumor efficacy, we simulated sustained release of IL-12 from a chitosan-based depot through a series of daily injections with fractionated doses of IL-12 alone. Specifically, weekly i.t. injections of chitosan/IL-12 were replaced by five daily injections with equal or decreasing microdoses of IL-12. Finally, to determine if chitosan potentiates the immunologic activity of IL-12, we performed a phenotypic analysis of immune cell subsets in spleens, tumors and tumor-draining lymph nodes (TDLNs) during immunotherapy.
Materials and methods

Laboratory animals
Female C57BL/6J mice, 8-to 12-weeks old, were obtained from the Jackson Laboratory (Bar Harbor, ME). All mice were housed and maintained under pathogenfree conditions in microisolator cages. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Arkansas. Animal care was in compliance with The Guide for Care and Use of Laboratory Animals (National Research Council).
Reagents
Dulbecco's modified Eagle's Medium (DMEM) was obtained from Hyclone Laboratories (Logan, Utah). Fetal bovine serum (FBS) was purchased from PAA Laboratories (Dartmouth, MA). Trypsin-versene/EDTA, penicillin, streptomycin, nonessential amino acid solution (NEAA), sodium pyruvate, HEPES and ACK lysis buffer were purchased from Lonza (Walkersville, MD). Dulbecco's phosphate-buffered saline (DPBS) and Hanks' balanced salt solution (HBSS) were purchased from Mediatech (Manassas, VA). Histopaque 1077 was obtained from MP Biomedicals (Solon, OH, USA). Cell aggregate dissociation buffer Accumax was purchased from Global Cell Solutions (Charlottesville, VA). Glucose, ethylenediaminetetraacetic acid (EDTA), and bovine serum albumin (BSA) were purchased from Amresco (Solon, OH). Sodium azide was purchased from Alfa Aesar (Ward Hill, MA). FACS buffer was comprised of PBS supplemented with 5 mM EDTA, 0.2% BSA, and 0.2% sodium azide. Chitosan glutamate, 200e600 kDa, 75e90% deacetylated (Protosan G 213) was purchased from NovaMatrix (Sandvika, Norway). Chitosan glutamate was reconstituted in DPBS to a final concentration of 1.5% (w/v) and henceforth referred to as chitosan solution. Recombinant murine IL-12 was purchased from PeproTech (Rocky Hill, NJ).
Fluorescence-labeled antibodies for flow cytometry were purchased from BD Biosciences (San Diego, CA) and include: anti-CD25 (clone: 7D4), anti-CD54 (clone: 3E2), anti-CD19 (clone: 1D3), anti-FoxP3 (clone: MF23), anti-I-Ab (clone: AF6-120.1), anti-CD3 (clone: 500A2), anti-IFN-g (clone: XMG1.2), anti-CD11b (clone: M1/70), anti-CD25 (clone: PC61), anti-NK1.1 (clone: PK136), anti-CD45 (clone: 30-F11), anti-CD4 (clone: RM4-5), anti-CD11c (clone: HL3), anti-CD8 (clone: 53-6.7), and anti-Gr-1 (clone: RB6-8C5).
Cells
The murine colon carcinoma cell line, MC38, was generously provided by Dr. Jeffrey Schlom (Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD). Cells were maintained in DMEM supplemented with 10% FBS, 1% NEAA, 1% HEPES, 1% L-glutamine, penicillin (100 IU/ml), and streptomycin (100 mg/ml). 
Statistical analysis
Differences in overall survival were analyzed using the logrank test. Differences in mean percentages of immune cell subsets were analyzed using Student's t-test with unpaired samples. P-values and hazard ratios were computed using GraphPad Prism 5.0 (GraphPad Software, Inc.; La Jolla, CA).
Results
Effect of chitosan/IL-12 injection location
To determine if the location of chitosan/IL-12 injection relative to tumor impacts antitumor activity, mice bearing established s.c. MC38 tumors received weekly doses of chitosan/IL-12 injected s.c. adjacent to the tumor, s.c. contralateral to the tumor or i.t. The growth of tumors in mice treated either adjacent or contralateral was delayed compared to DPBS-treated controls (Fig. 1A) . Adjacent injections were more effective than contralateral injections particularly at later timepoints. A survival analysis indicated that both adjacent (P < 0.001 vs. DPBS) and contralateral (P < 0.001 vs. DPBS) injections significantly increased overall survival (Fig. 1B) . Nevertheless, all mice treated with chitosan/IL-12 outside of the tumor developed progressive disease and had to be euthanized within 45 days. In contrast, 9 of 10 mice receiving i.t. injections of chitosan/IL-12 experienced complete tumor regression (Fig. 1A) . These mice remained tumor-free beyond 90 days (Fig. 1B) .
Simulating chitosan/IL-12 depot by microdosing
Our previous data demonstrated that chitosan solutions facilitated retention of co-formulated IL-12 for at least 5e6 days [22] . To explore the effect of enhanced retention on antitumor activity, an IL-12 depot was simulated through a series of daily i.t. injections.
One cohort of mice received fractionated doses of 0.2 mg IL-12 alone while a second cohort received decreasing daily doses of 1 mg, 0.25 mg, 0.12 mg, 0.08 mg and 0.05 mg IL-12 alone. Both depot simulations were administered for 5 consecutive days beginning on days 7, 14, 21 and 28 after tumor implantation. The fractionated doses simulated an even, sustained delivery of IL-12 to the tumor microenvironment. The intention of the decreasing dose schedule was to approximate the amount IL-12 remaining in the tumor following chitosan/IL-12 i.t. injection as determined previously [22] . Individual tumor growth curves revealed that 4/8 mice receiving the fractionated doses experienced complete tumor regression (Fig. 2B ) and long-term, tumor-free survival for at least 90 days (Fig. 2E) . The treatment regimen with decreasing doses led to tumor regression and long-term, tumor-free survival in 6/8 mice (Fig. 2C,E) . It should be noted that the total amount of IL-12 administered during the decreasing dose treatment was 50% greater than the fractionated dose schedule.
Similar to the injection location studies (Fig. 1) , i.t. chitosan/IL-12 (1 mg) eliminated tumors in 7/8 mice (Fig. 2D,E) . These mice remained tumor-free for at least 90 days (Fig. 2E ). There was no statistical difference in survival among the three IL-12 treated groups (P ¼ 0.26). However, a hazard ratio assessment indicated that mice treated i.t. with even fractionated doses or decreasing doses were 2.0 times and 4.4 times more likely to die, respectively, than mice treated with chitosan/IL-12.
Effect of i.t. treatment on leukocytic expansion
Figs. 1 and 2 demonstrate that chitosan was effective in augmenting the antitumor activity of IL-12 through sustained delivery to the tumor microenvironment. In an attempt to uncover additional antitumor mechanisms of chitosan beyond enhanced IL-12 retention, we looked for differences in immune cell populations in the spleens, tumor-draining lymph nodes and tumors of mice treated with DPBS, chitosan alone, IL-12 alone or chitosan/IL-12. Our current and previous data indicated that differences in tumor growth among these treatment groups start to become apparent 2e3 days after the second weekly injection. Therefore, immunophenotyping studies were focused 3 days after the second injection, i.e. day 17, when differences in leukocyte populations were expected to be greatest.
An assessment of the total number of leukocytes, revealed no differences between treatment groups in the spleen (Fig. 3) 
Effect of i.t. treatment on immune cell phenotype
In the spleen, phenotypic characterization of leukocyte populations revealed no significant differences in the percentages of
þ cells among the different treatment groups (data not shown). In the tumor, we observed increases in percentages of four potential effector populations, CD4 (Fig. 4A) ) increased from 1.2 AE 0.1 after DPBS to 3.4 AE 1.0% following chitosan/IL-12 injections (P ¼ 0.001). Treatment with chitosan alone was found to increase the percentage of total dendritic cells (P ¼ 0.0003 vs. DPBS), but not the percentage of mature dendritic cells (Fig. 4B) . IL-12 alone, on the other hand, increased the percentages of both total and mature dendritic cell subsets (P < 0.0001 and P ¼ 0.01, respectively). The percentage of CD4 þ cells decreased from 35.2 AE 5.4 after DPBS to 23.3 AE 5.6%, 18.8 AE 2.4% and 19.6 AE 2.6% following chitosan alone, IL-12 alone and chitosan/IL-12 injections, respectively. All CD4 þ decreases were significant vs. DPBS (P < 0.014).
We unexpectedly observed a large increase in Gr-1 þ CD11b þ cells in the tumor but not in spleens or TDLNs. Representative dot plots revealed strong double-positive populations in both chitosan and chitosan/IL-12-treated tumors (Fig. 5A) . The percentage of Gr-1 þ CD11b þ cells increased 3.9-fold in chitosan-treated tumors and 5.1-fold in chitosan/IL-12-treated tumors (Fig. 5B) . IL-12 alone treatment had no effect on this population.
Discussion
Our results indicate that injection site significantly influences antitumor activity of chitosan/IL-12. An injection of chitosan/IL-12 contralateral to the tumor functions as a systemic controlled release platform. In fact, we have previously shown that an s.c. injection of chitosan/IL-12 results in measurable levels of IL-12, as well as the downstream effector cytokine, IFN-g, in circulation [22] . Furthermore, our tumor growth delay data with contralateral chitosan/IL-12 are consistent with other delays observed using vector-based IL-12 delivery systems which also provide sustained systemic .
Placing the injection adjacent to the tumor resulted in better tumor control. This may be due to local increases in effector populations as observed in Figs. 3 and 4 . Therefore, peritumoral injections should be preferred over contralateral or distal injections due to their immunostimulatory influences on local draining lymph nodes and other immune cells in close proximity to the tumor. Nevertheless, for both contralateral and adjacent injections, it is clear that a sufficient amount of IL-12 is not available in the tumor microenvironment for complete tumor control.
In contrast, i.t. injections eliminated tumors in 9 of 10 ( Fig. 1B ) and 7 of 8 mice (Fig. 2D ). Not only does the i.t. route maximize IL-12 delivery to the tumor, but the i.t. injection itself may help disrupt the highly immunosuppressive tumor microenvironment. The literature contains numerous examples of cancer vaccines and immunotherapies which are more effective when delivered i.t. [25, 26] . I.t. injections are capable of producing a number of beneficial mechanical changes to the tumor including: 1) tumor necrosis through damage to tumor microvessels; 2) enhanced immune infiltrate through both damaged vessels and the subsequent wound healing response; and 3) disruption of the highly pressurized and poorly vascularized tumor architecture. Furthermore, the local availability of IL-12 is important as it has been shown to directly reverse immunosuppressive or tumor-supporting elements such as TAMs [27] , dysfunctional tumor-resident T cells [28, 29] , and T suppressor cells [30e32] .
Overcoming local immune suppression is critical to the success of cancer immunotherapies. It is suggested that the immunosuppressive tumor microenvironment limits the clinical responses of many cancer vaccines despite measurable adaptive responses in peripheral blood [33] . Our data support the notion that the i.t. route of administration is ideal for IL-12 and perhaps other antitumor cytokines.
Microdosing studies demonstrated that an IL-12 depot simulated through daily i.t. injections was nearly as effective in controlling tumors as weekly i.t. chitosan/IL-12. The evenly fractionated dose schedule, i.e. 0.2 mg IL-12 per day, appeared to perform slightly worse than the decreasing dose schedule in controlling tumor growth (Fig. 2) . However, it is noted that the decreasing dose schedule delivers 50% more IL-12 than the evenly fractionated schedule. Nevertheless, either microdosing schedule was more effective than weekly i.t. injections of IL-12 alone which resulted in only 10% long-term survival [22] . These data underscore the importance of sustained, local IL-12 for effective antitumor immunotherapy.
While the survival percentages of mice treated with daily microdoses and chitosan/IL-12 were statistically indistinguishable via logrank analysis, a hazard ratio assessment revealed that mice treated with even fractionated doses and decreasing doses were two to four times more likely to die than mice treated with chitosan/IL-12. Another substantial benefit of chitosan/IL-12 is the weekly administration schedule. Daily i.t. injections are, in general, not clinically practical.
In both the injection location and microdosing studies, mice that experienced complete tumor regression remained tumor-free for the duration of the study. This is consistent with our previous experiences with IL-12-based immunotherapies. We have treated a range of transplantable tumor models, including MC38, CT26, Panc02, B16 and 4T1, with various permutations of chitosan and IL-12-based immunotherapies (unpublished observation). We have yet to observe primary tumor recurrence following complete regression and 40e100% of cured mice are completely protected from tumor-specific rechallenge [22] . This is also consistent with the preclinical IL-12 literature [25, 34, 35] . The finding that chitosan/IL-12 outperformed the simulated IL-12 depots (Fig. 2) indicated a potential additional immunostimulatory role for chitosan that was investigated through phenotypic analyzes of immune cell populations. In order to maximize the opportunity to discover differences in immune cells with treatment, spleens, tumors and TDLNs were harvested shortly after two weekly i.t. injections. Our previous studies [22] , as well as Fig. 1 , indicated that treatment-related differences in tumor volumes become apparent after the second treatment.
As a rough approximation of immune stimulation, leukocytic expansion in both the tumor and TDLN was most pronounced with chitosan/IL-12 treatment (Fig. 3) . Chitosan alone and IL-12 alone also increased the number of leukocytes in tumors and TDLNs, albeit to a lesser extent. The finding that chitosan alone induced leukocyte expansion indicated that the polysaccharide had a stimulatory effect. Gross changes in leukocyte numbers were restricted to the local environment as none of the i.t. treatments affected splenocytes counts (Fig. 3A) .
While the T H 1-polarizing and antitumor mechanisms of IL-12 are well documented [35, 36] , the importance of immune effector populations during IL-12-mediated tumor regression is modeldependent. For example, IL-12-induced rejection of Sa1 ascites is driven by macrophages [37] , NK cells control metastatic MADB106 and 4T1 mammary adenocarcinomas [38, 39] , NK and NKT cells contribute to the control of B16 melanomas and RM-1 prostate carcinoma [40, 41] (Fig. 3) , the total number of NK cells increased substantially with chitosan/IL-12 immunotherapy. The percentage of NK1.1 þ CD3 þ (NKT) cells increased with chitosan/IL-12 treatment, however, it is not know if these cells were critical effectors since only NK cells were depleted with anti-asialo-GM1 in the previous study [22] . Percent CD4 þ cells, which were not necessary for chitosan/IL-12-mediated elimination of MC38 tumors [22] , were found to increase in tumors but decrease in TDLNs following i.t. chitosan/IL-12 (Fig. 4) . In the TDLN, the percentages of total and mature dendritic cells, which increased following IL-12 treatment, were further amplified by chitosan/IL-12.
Overall, results of the immunophenotyping studies implied that chitosan does not radically alter the distribution of immune effector cells but rather it amplifies IL-12-induced differences. It is not clear if these changes in distribution were mediated by the sustained presence of IL-12 in the tumor or if they were due to a unique property of chitosan. As shown in Fig. 2 , daily injections could have simulated sustained IL-12 in the tumor microenvironment, however, the potential of repeated injections to induce significant tumor damage and skew tumor infiltrates toward innate populations outweighed the benefit of such a study. Perhaps the most intriguing finding of the phenotyping studies was the massive increase in Gr-1 [22] . Separately, we (unpublished observation) and others [48] have found that mice injected with chitosan develop neither antibodies against chitosan nor chitosan-specific lymphoproliferative responses. Therefore, the Gr-1 þ CD11b þ increases are not associated with an adaptive response against chitosan. Consequently, in our context, Gr-1 þ CD11b þ cells are likely to be associated with an innate immune response that has no direct effector function, but may potentiate the adaptive response elicited by IL-12. Ongoing studies are focused on isolation and functional characterization of these cells.
Conclusion
Co-formulations of chitosan were found to enhance the antitumor efficacy of intratumorally administered IL-12. Chitosan did not appear to act via a novel effector pathway, but rather it amplified the traditional antitumor activities of IL-12 by providing sustained, high levels of the cytokine in the tumor microenvironment. In particular, IL-12-mediated increases in effector populations infiltrating the tumor and antigen presenting populations in draining lymph nodes were significantly enhanced through chitosan co-formulation. This localized delivery approach may overcome previous clinical failures with IL-12 that were due in part to the inability of i.v.-or s.c.-administered IL-12 to achieve biologically relevant concentrations of IL-12 in the tumor microenvironment at the maximum tolerated dose in humans. In addition, chitosan may also provide immunostimulatory signals which enhance antigen presentation in the regional environment. Beyond IL-12, the ease of co-formulation of chitosan with soluble proteins, make this an attractive platform for local, sustained delivery of any number of cytokines. Such a local delivery strategy is necessary for cytokine-based immunotherapies to fulfill their potential in the clinical management of cancer.
